- Home
- LRMR vs JYNT Comparison
LRMR vs JYNT Comparison
Compare LRMR & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- JYNT
- Stock Information
- Founded
- LRMR N/A
- JYNT 2010
- Country
- LRMR United States
- JYNT United States
- Employees
- LRMR N/A
- JYNT N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- LRMR Health Care
- JYNT Miscellaneous
- Exchange
- LRMR Nasdaq
- JYNT Nasdaq
- Market Cap
- LRMR 183.8M
- JYNT 170.1M
- IPO Year
- LRMR N/A
- JYNT 2014
- Fundamental
- Price
- LRMR $2.25
- JYNT $10.31
- Analyst Decision
- LRMR Strong Buy
- JYNT Strong Buy
- Analyst Count
- LRMR 9
- JYNT 1
- Target Price
- LRMR $19.00
- JYNT $15.00
- AVG Volume (30 Days)
- LRMR 1.4M
- JYNT 60.7K
- Earning Date
- LRMR 04-30-2025
- JYNT 05-08-2025
- Dividend Yield
- LRMR N/A
- JYNT N/A
- EPS Growth
- LRMR N/A
- JYNT N/A
- EPS
- LRMR N/A
- JYNT N/A
- Revenue
- LRMR N/A
- JYNT $51,896,605.00
- Revenue This Year
- LRMR N/A
- JYNT $10.88
- Revenue Next Year
- LRMR N/A
- JYNT $12.11
- P/E Ratio
- LRMR N/A
- JYNT N/A
- Revenue Growth
- LRMR N/A
- JYNT 10.47
- 52 Week Low
- LRMR $1.61
- JYNT $9.58
- 52 Week High
- LRMR $11.20
- JYNT $17.82
- Technical
- Relative Strength Index (RSI)
- LRMR 47.46
- JYNT 51.23
- Support Level
- LRMR $2.03
- JYNT $9.61
- Resistance Level
- LRMR $3.07
- JYNT $10.57
- Average True Range (ATR)
- LRMR 0.30
- JYNT 0.51
- MACD
- LRMR 0.01
- JYNT 0.07
- Stochastic Oscillator
- LRMR 31.12
- JYNT 71.10
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.